Urnov is a professor of molecular therapeutics at the University of California, Berkeley, and a director at its Innovative Genomics Institute. In May, news broke of a biomedical first: the on-demand ...

After teasing a new regulatory process for personalized genetic medicines at the end of last year, the FDA today unveiled draft guidance for an approval pathway that could see custom CRISPR therapies, ...

Imagine if, instead of delivering a leaflet individually to each home, a postal worker just had to give one to a volunteer on each block, who then photocopied it and handed out copies to neighbours.

A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child with a rare genetic disorder. Unlike earlier ...

Gene-editing techniques such as CRISPR-Cas9 have many uses in the area of food and agriculture. They can combat persistent drought and disease, and improve the colour and nutritional content of food ...

CRISPR gene drives bias inheritance in pests, advancing population-level control while raising questions about resistance and ecological governance.

Gene editing has enormous potential to help feed the world’s growing population, but it’s currently difficult, time-consuming ...

Gene editing figures to be part of the future of medicine, but a popular system for it has some room for improvement, researchers say. That’s why a team from UC San Diego in La Jolla set out with Yale ...

A new CRISPR-based tool that is directly used on patients' cancer cells can identify genes and regulatory elements driving ...

Researchers have unveiled a way to flip genes back on without slicing into the genome, a shift that could make CRISPR far safer and more flexible. Instead of cutting DNA, the new approach scrubs away ...

Aurora Therapeutics' first target is the rare inherited disease phenylketonuria, also known as PKU. Here at MIT Technology Review we’ve been writing about the gene-editing technology CRISPR since 2013 ...

NEW ORLEANS, LA—An investigational CRISPR-Cas9 gene-editing therapy that targets angiopoietin-like protein 3 (ANGPTL3), which has a role in regulating lipid metabolism, appears to safely lower levels ...